Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Chromatin activation underlying pathogenic mechanisms in MM & CLL

Iñaki Martín-Subero • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Multiple Myeloma

Iñaki Martín-Subero, PhD, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, describes a recent publication looking at chromatin activation as the underlying principle in pathogenic mechanisms in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Iñaki Martín-Subero

2:16
Tertiary structure, chromatin modifications and nuclear organisation in CLL
Iñaki Martín-Subero • 22 Sep 2019
2:12
Complete epigenome of CLL reveals important areas of dysregulation
Iñaki Martín-Subero • 25 Oct 2018
1:38
Therapeutically targeting transcription factors in CLL
Iñaki Martín-Subero • 25 Oct 2018
1:35
Shifting the focus in CLL: the epigenome
Iñaki Martín-Subero • 25 Oct 2018

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals